ArticleJAMA network open2025

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Pier Paolo Maria Berton Giachetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.